# US 2021/0069283 A1 · Method for regulating lipolysis and fatty acid oxidative metabolism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069283 A1
- Document ID: US20210069283A1
- Status: Published application
- Kind: A1
- Application number: 16/311,221
- Filed: 2016-11-24
- Published: 2021-03-11
- Earliest claimed: 2016-06-21
- Assignees: Nanjing University
- Applicants: Nanjing University
- Inventors: HUA ZICHUN; ZHUANG HONGQIN
- Web page: https://patentgrep.com/patent/US20210069283A1

## CPC

- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 14/4702: {Regulators; Modulating activity}
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- C40B 30/06: by measuring effects on living organisms, tissues or cells
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are a method for promoting the lipolysis and fatty acid oxidative metabolism in mammals or cells derived from mammals, a method for downregulating the fat content and the weight of a mammalian body, as well as a method for increasing the intracellular cAMP concentration, increasing the phosphorylation degree and the activity of the hormone-sensitive esterase HSL, enhancing the transcription activity of PPAR alpha and increasing the activities of enzymes involved in a fatty acid beta oxidation process. By simulating the expression of a protein corresponding to a gene responsible for the phosphorylation of the Fas-associated death domain protein, or treating and acting on mammals or cells derived from mammals with a material that can increase the phosphorylation degree of the Fas-associated death domain protein, said methods increases the phosphorylation of the Fas-associated death domain protein.

## Claims

### Claim 1

A method for promoting lipolysis and fatty acid oxidative metabolism of mammalian or mammalian-derived cells, or a method of lowering fat content and body weight in a mammal, or increasing intracellular cAMP concentration, increasing phosphorylation and activity of hormone-sensitive esterase HSL, or a method for enhancing PPARα transcriptional activity and increasing the activity of an enzyme involved in a fatty acid β-oxidation process wherein the method is carried out by up-regulating Fas-related death domain protein phosphorylation of mammalian or mammalian-derived cells.

### Claim 2 (depends on 1)

The methodp of claim 1, wherein the up-regulating Fas-related death domain protein phosphorylation of a mammalian or mammalian-derived cells is carried out by mimicking the expression of a protein corresponding to a gene of phosphorylated Fas-associated death domain protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mimicking the protein corresponding to a gene of phosphorylated Fas-associated death domain protein is a protein obtained by mutating the serine at position 194 of the wild-type Fas-associated death domain protein to aspartic acid or glutamic acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein the up-regulating Fas-related death domain protein phosphorylation of mammalian or mammalian-derived cells is carried out by treating mammalian or mammalian-derived cells by using a substance capable of increasing the phosphorylation level of Fas-related death domain protein in a mammalian or mammalian derived cell.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the mammal is a mouse or a human.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the enzyme involved in the fatty acid β-oxidation process includes peroxidase acyl-CoA oxidase 1, trihydroxy acyl-CoA dehydrogenase, very long-chain acyl-CoA dehydrogenase, long-chain acyl-CoA dehydrogenase, and mid-chain acyl-CoA dehydrogenase.

### Claim 7

A method for screening a substance capable of increasing Fas-related death domain protein phosphorylation, or screening for a substance capable of promoting lipolysis and fatty acid oxidative metabolism of mammalian or mammalian derived cells, or a method for screening a substance capable of lowering fat content and body weight in a mammal, or a method for screening a substance capable of increasing intracellular cAMP concentration, increasing the degree and activity of phosphorylation of a hormone-sensitive esterase HSL, enhancing PPARα transcriptional activity and increasing the activity of an enzyme involved in a fatty acid β-oxidation process, wherein the method is carried out by detecting the change in the phosphorylation level of Fas-associated death domain protein by Western Blot after the mammalian or mammalian-derived cells is exposed to a substance, and if the phosphorylation level is increased, it is considered that said substance has the activity of increasing the phosphorylation level of the Fas-related death domain protein of mammalian or mammalian-derived cells, or promoting lipolysis and fatty acid oxidative metabolism of mammalian or mammalian-derived cells, or lowering fat content and body weight in a mammal, or increasing intracellular cAMP concentration, increasing phosphorylation and activity of hormone-sensitive esterase HSL, and enhancing PPARα transcriptional activity and increasing the activity of an enzyme involved in a fatty acid β-oxidation process.

### Claim 8

A substance that increases the phosphorylation of Fas-associated death domain proteins in mammalian or mammalian-derived cells, wherein said substance comprises macromolecules that increase the phosphorylation level of Fas-related death domain protein: proteins, nucleic acids or polysaccharides; or small molecules: fatty acids, vitamins, natural products, chemically synthesized or chemically engineered products, small organic or inorganic molecules, or nanomolecules.

### Claim 9

A method of using a substance capable of increasing Fas-related death domain protein phosphorylation or a gene mimicking a gene of phosphorylated Fas-associated death domain proteins, or a protein expressed by the gene in preparation of a medicament for improving lipolysis and fatty acid oxidation metabolism; or a use of the substance, the gene, or the protein expressed by the gene in preparation of a medicament for lowering fat content and body weight in a mammal, or increasing intracellular cAMP concentration, increasing phosphorylation and activity of hormone-sensitive esterase HSL, enhancing PPARα transcriptional activity and increasing the activity of an enzyme involved in a fatty acid β-oxidation process.

### Claim 10 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein said method is used in combination with a method of promoting lipolysis and fatty acid oxidation metabolism by a chemotherapeutic agent, a method of promoting lipolysis and fatty acid oxidation metabolism by a Chinese medicine, a method of promoting lipolysis and fatty acid oxidation metabolism by a biological product, or a method of physically promoting lipolysis and fatty acid oxidation metabolism.

### Claim 11 (depends on 9)

The method of claim 9, wherein said substance is selected from a group consisting of: fatty acids, vitamins, natural products, chemically synthesized or chemically engineered products, small organic or inorganic molecules, and nanomolecules. .
